RxDoctor Payments Data

Scott Jorgensen, MD

Internal Medicine · Mequon, WINPI 1184654725

Payments from drug & device makers

$895in general payments, 2019–2025

Across 13 payments — averaging $68.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$157
  • Abbott$148
  • Biohaven Pharmaceuticals, Inc.$125
  • Boehringer Ingelheim$125
  • GSK$124
  • E.r. Squibb & Sons, L.L.C.$121
  • plus $97 from 3 others

What the payments were for

  • Food & beverage$895100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$895 in reported general payments places this provider in the 85th percentile of 1,411 internal medicine providers in Wisconsin.

See all internal medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$144,032
Medicare patients
370
Services billed
1,716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban142$141,586
MounjaroTirzepatide47$61,891
JardianceEmpagliflozin44$44,661
OzempicSemaglutide21$32,546
JanuviaSitagliptin Phosphate37$29,638
XareltoRivaroxaban13$16,089
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$13,899
Xtampza ErOxycodone Myristate16$11,908
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$11,025
Losartan Potassium1,025$10,389
LivaloPitavastatin Calcium13$9,246
Atorvastatin Calcium835$7,605
SynthroidLevothyroxine Sodium100$6,982
Levothyroxine Sodium584$5,614
Amlodipine Besylate749$5,414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$125$44,66144 claims
Novo NordiskOzempic$157$32,54621 claims
GSKAnoro Ellipta, Trelegy Ellipta$124$24,92330 claims
AbbVieSynthroid$51$6,982100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,411 internal medicine providers in Wisconsin.

Other internal medicine in Mequon

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →